ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,272 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentZugNektar Therapeutics Europe GmbH
Nektar Therapeutics Europe GmbH Logo
Verified· 2 sources

Nektar Therapeutics Europe GmbH

Summary

About the company

Nektar Therapeutics Europe GmbH develops novel therapies for autoimmune and inflammatory diseases according to the information presented on the website. Its work focuses on immune modulation, including investigational medicines targeting regulatory T cells and other immunology pathways.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Pharmaceutical Industry
✓ Offered6
Research and development of immunomodulatory medicines
Research and development of novel therapies for autoimmune diseases and chronic inflammation; focus on immune modulation, regulatory T cells and disease-modifying agents.
Clinical trials
Clinical trials for investigational medicines, including REZOLVE-AD in atopic dermatitis and REZOLVE-AA in alopecia areata; information on phase, status and participation.
Biologics development for immune disorders
Development of biologic agents such as rezpegaldesleukin and NKTR-0165 for autoimmune diseases, chronic inflammation, vitiligo, multiple sclerosis and other immunology disorders.
Oncology drug development
Development of the IL-15 receptor agonist NKTR-255 for solid tumours and large B-cell lymphoma; studied in combination with checkpoint inhibitors and cell therapies.
Strategic partnerships in drug development
Partnerships with pharmaceutical and biotechnology companies across preclinical to late-stage development; collaboration on therapies that have already produced approved medicines.
Scientific publications and research information
Scientific background on immunology and T-cell regulation, plus publications on the research approach and therapeutic development available on the website.
Comparisons

Nektar Therapeutics Europe GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Nektar Therapeutics Europe GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Nektar Therapeutics Europe GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Zählerweg 6
6300 Zug

At a glance

Legal form
Limited Liability Company
UID
CHE-328.444.575
Founded
2021 · 5 years
Last commercial register change
July 13, 2026
Employees
1 to 10

Knowledge

No knowledge articles yet

Once Nektar Therapeutics Europe GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

DP
Deciphera Pharmaceuticals (Schweiz) AG
Zug
AS
Alnylam Switzerland GmbH
Zug
AI
Apellis International GmbH
Zug
JP
Jazz Pharmaceuticals Switzerland GmbH
Zug
ME
Meditrial Europe AG
Zug
RP
Rhythm Pharmaceuticals Switzerland GmbH
Zug
NA
Novelpharm AG
Zug
PR
Premier Research Group SA
Zug